Bismuth concentration in blood and urine of children treated with ventrisol (polfa) preliminary study.
The bismuth concentration was measured in the blood and urine of 21 children from 8 to 17 years old (13.12 +/- 2.67) treated with Ventrisol (Polfa)-tripotassium dicitrato bismuthate (TDB). One tablet of TDB-equivalent to 120 mg Bi2O3. One tablet was given orally to the patients four times a day. Blood and urine was taken for measurement of bismuth concentration in the morning, on fasting, before the administration of Ventrisol on the 6-8 days, the 27-28 days of the therapy and in the 4-5, 8-9 weeks after TDB therapy. The reason for TDB treatment was chronic gastritis and/or duodenal ulcers, which were diagnosed by endoscopic examination. No bismuth in the blood and a very low concentration in the urine were determined in 19 children before TDB treatment. After 6-8 days of TDB treatment the bismuth concentration in the blood was 40.85 +/- 31.05 micrograms/L and 75.11 +/- 82.07 micrograms/L in the urine. In the 27-28 days of the treatment the bismuth concentration in the blood was 37.67 +/- 25.06 micrograms/L, and 163.56 +/- 181.86 micrograms/L in the urine. In the 4-5 weeks after the TDB treatment the bismuth concentration in the blood was 7.77 +/- 10.56 micrograms/L, and 15.72 +/- 9.87 micrograms/L in the urine. The bismuth concentration level in the urine rose together with the rise of the bismuth concentration level in the blood, the correlation factor was r = 0.68. No symptoms of side effects caused by the TDB treatment were observed. Before the treatment a high bismuth concentration was found in the blood of two patients. These cases are discussed later.
Iwańczak
F
F
Department of Pediatrics and Gastroenterology, Medical Academy of Wrocław.
Rajska
H
H
Iwańczak
B
B
Górecka
H
H
D000293:Adolescent; D001729:Bismuth / Q000097:blood / Q000378:metabolism* / Q000652:urine; D002648:Child; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005756:Gastritis / Q000188:drug therapy*; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010865:Pilot Projects
D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate; D001729:Bismuth